Literature DB >> 33308315

Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma.

Ming Li1, Guoping Li2, Juri Kiyokawa1, Zain Tirmizi1, Leland G Richardson1, Jianfang Ning1,3, Saumya Das2, Robert L Martuza1, Anat Stemmer-Rachamimov4, Samuel D Rabkin5, Hiroaki Wakimoto6.   

Abstract

Cancer-associated fibroblasts (CAFs) are activated fibroblasts constituting the major stromal components in many types of cancer. CAFs contribute to hallmarks of cancer such as proliferation, invasion and immunosuppressive tumor microenvironment, and are associated with poor prognosis of patients with cancer. However, in glioblastoma (GBM), the most common and aggressive primary malignant brain tumor, our knowledge about CAFs or CAF-like stromal cells is limited. Here, using commonly accepted CAF markers, we characterized CAF-like cell populations in clinical glioma specimens and datasets along with mouse models of GBM. We found that tumor-associated pericytes marked by co-expression of fibroblast activation protein α (FAP) and PDGFRβ represent major stromal cell subsets in both human GBM and mouse GBM models, while a fraction of mesenchymal neoplastic cells also express FAP in patient tumors. Since oncolytic viruses can kill cancer cells and simultaneously modulate the tumor microenvironment by impacting non-neoplastic populations such as immune cells and tumor vasculature, we further investigated the ability of oncolytic viruses to target GBM-associated stromal cells. An oncolytic adenovirus, ICOVIR15, carrying ∆24-E1A and an RGD-fiber, infects and depletes FAP+ pericytes as well as GBM cells in murine GBM. Our study thus identifies FAP+/PDGFRβ+ pericytes as a major CAF-like stromal cell population in GBM, and highlights the unique property of this oncolytic adenovirus to target both GBM cells and GBM-associated stromal FAP+ cells.

Entities:  

Keywords:  FAP; Glioblastoma; Oncolytic virus; Pericytes; Tumor-associated fibroblasts

Year:  2020        PMID: 33308315     DOI: 10.1186/s40478-020-01096-0

Source DB:  PubMed          Journal:  Acta Neuropathol Commun        ISSN: 2051-5960            Impact factor:   7.801


  52 in total

Review 1.  Immunological hallmarks of stromal cells in the tumour microenvironment.

Authors:  Shannon J Turley; Viviana Cremasco; Jillian L Astarita
Journal:  Nat Rev Immunol       Date:  2015-10-16       Impact factor: 53.106

2.  Suppression of antitumor immunity by stromal cells expressing fibroblast activation protein-alpha.

Authors:  Matthew Kraman; Paul J Bambrough; James N Arnold; Edward W Roberts; Lukasz Magiera; James O Jones; Aarthi Gopinathan; David A Tuveson; Douglas T Fearon
Journal:  Science       Date:  2010-11-05       Impact factor: 47.728

3.  CD10+GPR77+ Cancer-Associated Fibroblasts Promote Cancer Formation and Chemoresistance by Sustaining Cancer Stemness.

Authors:  Shicheng Su; Jianing Chen; Herui Yao; Jiang Liu; Shubin Yu; Liyan Lao; Minghui Wang; Manli Luo; Yue Xing; Fei Chen; Di Huang; Jinghua Zhao; Linbin Yang; Dan Liao; Fengxi Su; Mengfeng Li; Qiang Liu; Erwei Song
Journal:  Cell       Date:  2018-01-25       Impact factor: 41.582

4.  Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma.

Authors:  Steven J Cohen; R Katherine Alpaugh; Irma Palazzo; Neal J Meropol; André Rogatko; Zhiheng Xu; John P Hoffman; Louis M Weiner; Jonathan D Cheng
Journal:  Pancreas       Date:  2008-08       Impact factor: 3.327

5.  The reprogramming of tumor stroma by HSF1 is a potent enabler of malignancy.

Authors:  Ruth Scherz-Shouval; Sandro Santagata; Marc L Mendillo; Lynette M Sholl; Irit Ben-Aharon; Andrew H Beck; Dora Dias-Santagata; Martina Koeva; Salomon M Stemmer; Luke Whitesell; Susan Lindquist
Journal:  Cell       Date:  2014-07-31       Impact factor: 41.582

6.  Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer.

Authors:  Ana Costa; Yann Kieffer; Alix Scholer-Dahirel; Floriane Pelon; Brigitte Bourachot; Melissa Cardon; Philemon Sirven; Ilaria Magagna; Laetitia Fuhrmann; Charles Bernard; Claire Bonneau; Maria Kondratova; Inna Kuperstein; Andrei Zinovyev; Anne-Marie Givel; Maria-Carla Parrini; Vassili Soumelis; Anne Vincent-Salomon; Fatima Mechta-Grigoriou
Journal:  Cancer Cell       Date:  2018-02-15       Impact factor: 31.743

7.  Stromal Microenvironment Shapes the Intratumoral Architecture of Pancreatic Cancer.

Authors:  Matteo Ligorio; Srinjoy Sil; Jose Malagon-Lopez; Linda T Nieman; Sandra Misale; Mauro Di Pilato; Richard Y Ebright; Murat N Karabacak; Anupriya S Kulkarni; Ann Liu; Nicole Vincent Jordan; Joseph W Franses; Julia Philipp; Johannes Kreuzer; Niyati Desai; Kshitij S Arora; Mihir Rajurkar; Elad Horwitz; Azfar Neyaz; Eric Tai; Neelima K C Magnus; Kevin D Vo; Chittampalli N Yashaswini; Francesco Marangoni; Myriam Boukhali; Jackson P Fatherree; Leah J Damon; Kristina Xega; Rushil Desai; Melissa Choz; Francesca Bersani; Adam Langenbucher; Vishal Thapar; Robert Morris; Ulrich F Wellner; Oliver Schilling; Michael S Lawrence; Andrew S Liss; Miguel N Rivera; Vikram Deshpande; Cyril H Benes; Shyamala Maheswaran; Daniel A Haber; Carlos Fernandez-Del-Castillo; Cristina R Ferrone; Wilhelm Haas; Martin J Aryee; David T Ting
Journal:  Cell       Date:  2019-05-30       Impact factor: 41.582

Review 8.  The Dark Side of Fibroblasts: Cancer-Associated Fibroblasts as Mediators of Immunosuppression in the Tumor Microenvironment.

Authors:  Lea Monteran; Neta Erez
Journal:  Front Immunol       Date:  2019-08-02       Impact factor: 7.561

Review 9.  A framework for advancing our understanding of cancer-associated fibroblasts.

Authors:  Erik Sahai; Igor Astsaturov; Edna Cukierman; David G DeNardo; Mikala Egeblad; Ronald M Evans; Douglas Fearon; Florian R Greten; Sunil R Hingorani; Tony Hunter; Richard O Hynes; Rakesh K Jain; Tobias Janowitz; Claus Jorgensen; Alec C Kimmelman; Mikhail G Kolonin; Robert G Maki; R Scott Powers; Ellen Puré; Daniel C Ramirez; Ruth Scherz-Shouval; Mara H Sherman; Sheila Stewart; Thea D Tlsty; David A Tuveson; Fiona M Watt; Valerie Weaver; Ashani T Weeraratna; Zena Werb
Journal:  Nat Rev Cancer       Date:  2020-01-24       Impact factor: 60.716

Review 10.  In search of definitions: Cancer-associated fibroblasts and their markers.

Authors:  Martin Nurmik; Pit Ullmann; Fabien Rodriguez; Serge Haan; Elisabeth Letellier
Journal:  Int J Cancer       Date:  2019-02-28       Impact factor: 7.396

View more
  8 in total

Review 1.  Metabolic Regulation of Fibroblast Activation and Proliferation during Organ Fibrosis.

Authors:  Sudan Wang; Yan Liang; Chunsun Dai
Journal:  Kidney Dis (Basel)       Date:  2022-03-03

Review 2.  Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies.

Authors:  Johannes P W Heidbuechel; Christine E Engeland
Journal:  J Hematol Oncol       Date:  2021-04-16       Impact factor: 17.388

Review 3.  Infection of non-cancer cells: A barrier or support for oncolytic virotherapy?

Authors:  Victor A Naumenko; Aleksei A Stepanenko; Anastasiia V Lipatova; Daniil A Vishnevskiy; Vladimir P Chekhonin
Journal:  Mol Ther Oncolytics       Date:  2022-02-12       Impact factor: 7.200

4.  Procollagen-Lysine, 2-Oxoglutarate 5-Dioxygenase Family: Novel Prognostic Biomarkers and Tumor Microenvironment Regulators for Lower-Grade Glioma.

Authors:  Siming Gong; Changwu Wu; Franziska Köhler; Jürgen Meixensberger; Nikolas Schopow; Sonja Kallendrusch
Journal:  Front Cell Neurosci       Date:  2022-02-18       Impact factor: 5.505

Review 5.  Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.

Authors:  Yaomei Tian; Daoyuan Xie; Li Yang
Journal:  Signal Transduct Target Ther       Date:  2022-04-06

Review 6.  Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy.

Authors:  Zhongbing Qi; Xiangyu Long; Jiyan Liu; Ping Cheng
Journal:  Front Cell Neurosci       Date:  2022-09-09       Impact factor: 6.147

Review 7.  Oncogenesis, Microenvironment Modulation and Clinical Potentiality of FAP in Glioblastoma: Lessons Learned from Other Solid Tumors.

Authors:  Yixin Shi; Ziren Kong; Penghao Liu; Guozhu Hou; Jiaming Wu; Wenbin Ma; Xin Cheng; Yu Wang
Journal:  Cells       Date:  2021-05-10       Impact factor: 6.600

Review 8.  Cancer-Associated Fibroblast Heterogeneity: A Factor That Cannot Be Ignored in Immune Microenvironment Remodeling.

Authors:  Pei-Yu Chen; Wen-Fei Wei; Hong-Zhen Wu; Liang-Sheng Fan; Wei Wang
Journal:  Front Immunol       Date:  2021-07-08       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.